Filing Flows › Comparisons › CUE vs PRAX
Cue Biopharma vs Praxis Precision Medicines: CUE and PRAX compared
Cue Biopharma is the larger company: $7.9M of revenue in its latest quarter (Q2 2026) against $7.5M for Praxis Precision Medicines (Q4 2024). Praxis Precision Medicines is growing faster (14× against +167% a year earlier).
Where the money goes: CUE and PRAX
Cue Biopharma (CUE) · Q2 2026
Cue Biopharma, Q2 2026: revenue $7.9M (+167% year over year), net loss $153M, operating cash flow −$29.0M. The chart follows the revenue to costs, profit and cash.
Praxis Precision Medicines (PRAX) · Q4 2024
Praxis Precision Medicines, Q4 2024: revenue $7.5M (14× year over year), operating margin -857.0%, net loss $58.7M, operating cash flow −$56.1M. The chart follows the revenue to costs, profit and cash.
| Cue Biopharma (CUE) | Praxis Precision Medicines (PRAX) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q4 2024 |
| Revenue | $7.9M | $7.5M |
| Revenue growth, Y/Y | +167% | 14× |
| Operating margin | n/m | -857.0% |
| Net earnings | −$153M | −$58.7M |
| Net margin | — | -786.3% |
| Operating cash flow | −$29.0M | −$56.1M |
| Market value | — | $8.3B |
| Analysts’ mean target | — | $650.00 |
Questions
Which is bigger, Cue Biopharma or Praxis Precision Medicines?
Cue Biopharma is the larger company: $7.9M of revenue in its latest quarter (Q2 2026) against $7.5M for Praxis Precision Medicines (Q4 2024).
Is Cue Biopharma or Praxis Precision Medicines growing faster?
Praxis Precision Medicines is growing faster (14× against +167% a year earlier).
More: Cue Biopharma earnings · how Cue Biopharma makes money · Praxis Precision Medicines earnings · how Praxis Precision Medicines makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 14, 2026; 10-K filed Feb 28, 2025). Fiscal quarters can end on different dates. Not investment advice.